Water Island Capital LLC purchased a new stake in Osiris Therapeutics, Inc. (OTCMKTS:OSIR) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 257,485 shares of the biotechnology company’s stock, valued at approximately $4,892,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. purchased a new position in Osiris Therapeutics during the third quarter valued at approximately $260,000. Bank of New York Mellon Corp purchased a new position in Osiris Therapeutics during the third quarter valued at approximately $114,000. Renaissance Technologies LLC purchased a new position in Osiris Therapeutics during the third quarter valued at approximately $351,000. Vanguard Group Inc. purchased a new position in Osiris Therapeutics during the third quarter valued at approximately $7,936,000. Finally, Vanguard Group Inc purchased a new position in Osiris Therapeutics during the third quarter valued at approximately $7,936,000. 0.28% of the stock is currently owned by institutional investors.

OSIR stock remained flat at $$18.99 during midday trading on Wednesday. Osiris Therapeutics, Inc. has a one year low of $7.01 and a one year high of $19.30.

Separately, TheStreet raised shares of Osiris Therapeutics from a “c+” rating to a “b-” rating in a research note on Friday, January 25th.

TRADEMARK VIOLATION WARNING: “Water Island Capital LLC Purchases Shares of 257,485 Osiris Therapeutics, Inc. (OSIR)” was published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.mareainformativa.com/news/2019/05/15/water-island-capital-llc-purchases-shares-of-257485-osiris-therapeutics-inc-osir.html.

Osiris Therapeutics Profile

Osiris Therapeutics, Inc researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints.

See Also: Understanding Market Liquidity

Want to see what other hedge funds are holding OSIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Osiris Therapeutics, Inc. (OTCMKTS:OSIR).

Institutional Ownership by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

Receive News & Ratings for Osiris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.